Rami Manochakian/X
Jul 21, 2025, 15:04
Rami Manochakian: FLAURA2 Trial Update on EGFR+ Advanced Lung Cancer
Rami Manochakian, Vice President of the North American Neuroendocrine Tumor Society, shared a post on X:
“Hot Off the Press. Big News Press Release by AstraZeneca.
FLAURA2 trial of Osimertinib + Chemotherapy vs Osimertinib in 1st line Therapy for patients with EGFR+ advanced Lung Cancer (NSCLC) shows: Statistically Significant and Clinically Meaningful Improvement in Overall Survival.”
More posts featuring Rami Manochakian.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 12, 2025, 16:02
Aug 12, 2025, 15:59
Aug 12, 2025, 15:50
Aug 12, 2025, 15:43
Aug 12, 2025, 15:37
Aug 12, 2025, 15:30
Aug 12, 2025, 15:29
Aug 12, 2025, 15:21